pyridoxine has been researched along with Chronic Kidney Failure in 92 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure." | 9.10 | Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002) |
| "Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy." | 9.09 | Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. ( Chadefaux-Vekemans, B; Drüeke, T; Jungers, P; Massy, ZA; Touam, M; Zingraff, J, 1999) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 7.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear." | 7.70 | Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function." | 7.69 | Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. ( Bergstralh, EJ; Eickholt, JT; Milliner, DS; Smith, LH; Wilson, DM, 1994) |
| " With regard to the assembled results the authors recommend in addition to monitoring of vitamin C also monitoring of vitamin B6 in plasma during long-term administration of large doses of furosemide to patients with chronic renal failure as deficiency of these vitamins could develop." | 5.30 | [The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure]. ( Derzsiová, K; Mydlík, M; Rajnic, A; Zemberová, E, 1998) |
| "Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure." | 5.10 | Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002) |
| "Hyperhomocysteinemia occurs in nearly 100% of patients with end-stage renal disease (ESRD) and is associated with increased morbidity and mortality." | 5.09 | Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. ( Bosselmann, KP; Dierkes, J; Domröse, U; Luley, C; Neumann, KH, 2001) |
| "Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy." | 5.09 | Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. ( Chadefaux-Vekemans, B; Drüeke, T; Jungers, P; Massy, ZA; Touam, M; Zingraff, J, 1999) |
| "Hyperhomocysteinemia refers to an elevated circulating level of the sulfur-containing amino acid homocysteine and has been shown to be a risk factor for vascular disease in the general population." | 4.80 | Homocysteine and renal disease. ( Robinson, K; van Guldener, C, 2000) |
| "The concept of a short, high-dose induction therapy with intravenous folic acid, pyridoxine, cyanocobalamin, and a subsequent low-dose maintenance regimen is effective in the treatment of hyperhomocysteinemia in patients with ESRD." | 3.72 | Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study. ( Gerhardt, T; Klehr, HU; Look, M; Pöge, U; Sauerbruch, T; Woitas, RP, 2004) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 3.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia has been increasingly recognized as an important risk factor for elevated atherosclerotic vascular disease in chronic renal failure." | 3.70 | [Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement]. ( Graefe, U; Henning, BF; Tepel, M; Zidek, W, 2000) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear." | 3.70 | Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function." | 3.69 | Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. ( Bergstralh, EJ; Eickholt, JT; Milliner, DS; Smith, LH; Wilson, DM, 1994) |
| "Three dialysis patients with extrapulmonary tuberculosis developed confusion 4-14 days after commencement of treatment with anti-tuberculosis drugs, despite the use of prophylactic pyridoxine." | 3.68 | Isoniazid induced encephalopathy in dialysis patients. ( Cheng, IK; Cheung, WC; Ip, M; Lo, CY; Lo, WK, 1993) |
| "Treatment of tuberculosis in a hemodialysis patient with isoniazid, rifampin, and pyrazinamide resulted in the development of acute cerebellar dysfunction." | 3.68 | Cerebellar syndrome caused by isoniazid. ( Blumberg, EA; Gil, RA, 1990) |
| "05) with three vitamin dosages weekly, but not with one dosage weekly." | 2.70 | Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate. ( Graefe, U; Henning, BF; Riezler, R; Tepel, M; Zidek, W, 2001) |
| "Bone marrow smears from 20 patients with chronic renal failure and on regular haemodialysis treatment (RDT) were morphologically analysed." | 2.65 | The influence of vitamin B6 supplementation on the bone marrow morphology in patients on regular haemodialysis treatment. A double-blind study. ( Lindholm, T; Sjögren, U; Thysell, H, 1979) |
| "Type 1 primary hyperoxaluria is a genetic disorder caused by deficiency of the liver-specific peroxisomal enzyme alanine-glyoxylate aminotransferase." | 2.49 | Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. ( Fillaus, JA; Plumb, TJ; Swee, ML, 2013) |
| " The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements." | 2.40 | Is there a role for adjuvant therapy in patients being treated with epoetin? ( Hörl, WH, 1999) |
| "Primary hyperoxaluria type I is a metabolic disorder caused by the deficiency of the peroxisomal alanine:glyoxylate aminotransferase." | 2.38 | Primary hyperoxaluria type I. ( Brodehl, J; Latta, K, 1990) |
| "Primary hyperoxaluria is a rare genetic disorder characterized by oxalate overproduction, leading to kidney failure due to nephrocalcinosis, and is eventually responsible for systemic oxalosis." | 1.48 | Type 1 primary hyperoxaluria: A case report and focus on bone impairment of systemic oxalosis. ( Boivin, G; Caillard, S; Javier, RM; Pijnenburg, L; Rizzo, S, 2018) |
| "ESRD was the commonest presenting manifestation in two-thirds of our cohort." | 1.46 | Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center. ( Abdelaziz, H; Abdelrahman, SM; Badr, AM; Bazaraa, HM; Eweeda, KM; Fayez, A; Ghanim, K; Helmy, R; Kotb, MA; Nabhan, MM; Soliman, NA; Tolba, OA, 2017) |
| " With regard to the assembled results the authors recommend in addition to monitoring of vitamin C also monitoring of vitamin B6 in plasma during long-term administration of large doses of furosemide to patients with chronic renal failure as deficiency of these vitamins could develop." | 1.30 | [The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure]. ( Derzsiová, K; Mydlík, M; Rajnic, A; Zemberová, E, 1998) |
| "In the majority of patients with chronic renal failure and in patients during various forms of renal replacement therapy can develop vitamin B6 deficiency from many causes." | 1.30 | Metabolism of vitamin B6 and its requirement in chronic renal failure. ( Derzsiová, K; Mydlík, M; Zemberová, E, 1997) |
| "Thus, vitamin B6 deficiency in chronically uremic rats administered with large amounts of methionine may reduce growth, lower renal function and cause abnormal metabolism of sulfur-containing amino acids." | 1.29 | Content of sulfur amino acids and vitamin B6 and related enzyme activities in rats with chronic renal failure fed a high methionine diet. ( Asagi, K; Awata, S; Kobayashi, M; Kodama, H; Nakayama, K; Nakayama, M, 1996) |
| "The detection of type I primary hyperoxaluria is based on the finding of exceedingly high oxalate excretion which is associated with increased glycolate excretion." | 1.28 | Glycolate determination detects type I primary hyperoxaluria in dialysis patients. ( Bianco, O; Finocchiaro, P; Linari, F; Marangella, M; Petrarulo, M; Vitale, C, 1991) |
| "We conclude that pyridoxine deficiency does not contribute significantly to hyperoxalaemia in patients receiving dialysis and that 100 mg of pyridoxine daily is insufficient to reduce oxalate generation by a pharmacological action on glycine transamination." | 1.28 | Effect of pyridoxine supplementation on plasma oxalate concentrations in patients receiving dialysis. ( Channon, SM; Laker, MK; Parkinson, IS; Sheldon, WS; Tomson, CR; Ward, MK, 1989) |
| "Serum fluorescence in patients with chronic renal failure was significantly higher than in normals and patients with jaundice." | 1.27 | Fluorometric study of serum in patients with chronic renal failure. ( Digenis, GE; Hadjivassiliou, AG; Mayopoulou-Symvoulidis, D; Symvoulidis, A; Tsaparas, N; Voudiclari, S, 1984) |
| "This case illustrates that despite recurrence of oxalate stones in the allograft, satisfactory renal function can be maintained by careful follow-up and appropriate interventions." | 1.27 | Successful renal transplantation in hyperoxaluria. A report of two cases. ( Alison, DV; Curtis, J; Diethelm, AG; Luke, RG; Whelchel, JD, 1983) |
| "Vitamin B6 deficiency was evaluated in 37 patients with chronic renal failure and in 71 patients undergoing maintenance hemodialysis (HD) or intermittent peritoneal dialysis (PD)." | 1.26 | Daily requirement for pyridoxine supplements in chronic renal failure. ( Blumenkrantz, MJ; Card, B; Casciato, DA; Jones, MR; Kopple, JD; Mercurio, K; Roberts, C; Saltzman, R; Swendseid, ME; Tallos, J, 1981) |
| "In patients with chronic renal failure on potatoe-egg-diet (0." | 1.25 | [Vitamin B6-deficiency and -substitution in chronic uremia (author's transl)]. ( Gäng, V; Heidland, A; Kult, J; Schulz, RJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (34.78) | 18.7374 |
| 1990's | 36 (39.13) | 18.2507 |
| 2000's | 18 (19.57) | 29.6817 |
| 2010's | 5 (5.43) | 24.3611 |
| 2020's | 1 (1.09) | 2.80 |
| Authors | Studies |
|---|---|
| Lorenz, EC | 1 |
| Lieske, JC | 1 |
| Seide, BM | 1 |
| Olson, JB | 1 |
| Mehta, R | 1 |
| Milliner, DS | 3 |
| Pijnenburg, L | 1 |
| Caillard, S | 1 |
| Boivin, G | 1 |
| Rizzo, S | 1 |
| Javier, RM | 1 |
| Plumb, TJ | 1 |
| Swee, ML | 1 |
| Fillaus, JA | 1 |
| Chaitanya, V | 1 |
| Sangeetha, B | 1 |
| Reddy, MH | 1 |
| Venkata Kumar, AC | 1 |
| Ram, R | 1 |
| Sivakumar, V | 1 |
| Soliman, NA | 1 |
| Nabhan, MM | 1 |
| Abdelrahman, SM | 1 |
| Abdelaziz, H | 1 |
| Helmy, R | 1 |
| Ghanim, K | 1 |
| Bazaraa, HM | 1 |
| Badr, AM | 1 |
| Tolba, OA | 1 |
| Kotb, MA | 1 |
| Eweeda, KM | 1 |
| Fayez, A | 1 |
| Hoppe, B | 1 |
| Beck, BB | 1 |
| Gill, H | 1 |
| Yip, T | 1 |
| So, CC | 1 |
| Lo, WK | 2 |
| Pöge, U | 1 |
| Look, M | 1 |
| Gerhardt, T | 1 |
| Klehr, HU | 1 |
| Sauerbruch, T | 1 |
| Woitas, RP | 1 |
| Jamison, RL | 2 |
| Hartigan, P | 2 |
| Gaziano, JM | 2 |
| Fortmann, SP | 2 |
| Goldfarb, DS | 2 |
| Haroldson, JA | 1 |
| Kaufman, J | 1 |
| Lavori, P | 1 |
| McCully, KS | 1 |
| Robinson, K | 5 |
| Demir, K | 1 |
| Akyüz, F | 1 |
| Aysuna, N | 1 |
| Nanayakkara, PW | 1 |
| van Guldener, C | 3 |
| ter Wee, PM | 2 |
| Scheffer, PG | 1 |
| van Ittersum, FJ | 1 |
| Twisk, JW | 1 |
| Teerlink, T | 1 |
| van Dorp, W | 1 |
| Stehouwer, CD | 2 |
| Kaufman, JS | 1 |
| Warren, SR | 1 |
| Guarino, PD | 1 |
| Lacour, B | 1 |
| Parry, C | 1 |
| Drüeke, T | 2 |
| Touam, M | 2 |
| Kreis, H | 1 |
| Bailly, M | 1 |
| Durand, D | 1 |
| Whelchel, JD | 1 |
| Alison, DV | 1 |
| Luke, RG | 1 |
| Curtis, J | 1 |
| Diethelm, AG | 1 |
| Bohannon, LL | 1 |
| Norman, DJ | 1 |
| Barry, J | 1 |
| Bennett, WM | 1 |
| Scheinman, JI | 2 |
| Najarian, JS | 1 |
| Mauer, SM | 1 |
| de Zegher, FE | 1 |
| Wolff, ED | 1 |
| vd Heijden, AJ | 1 |
| Sukhai, RN | 1 |
| Casciato, DA | 2 |
| McAdam, LP | 1 |
| Kopple, JD | 2 |
| Bluestone, R | 1 |
| Goldberg, LS | 1 |
| Clements, PJ | 1 |
| Knutson, DW | 1 |
| Hadjivassiliou, AG | 1 |
| Digenis, GE | 1 |
| Mayopoulou-Symvoulidis, D | 1 |
| Voudiclari, S | 1 |
| Tsaparas, N | 1 |
| Symvoulidis, A | 1 |
| Balcke, P | 4 |
| Schmidt, P | 3 |
| Zazgornik, J | 3 |
| Kopsa, H | 3 |
| O'Regan, PF | 1 |
| Joekes, AM | 1 |
| Deutsch, E | 1 |
| Kamata, K | 3 |
| Okubo, M | 3 |
| Marumo, F | 3 |
| Nango, H | 1 |
| Higashishiba, H | 1 |
| Kanayama, K | 1 |
| Koyama, R | 1 |
| Mercurio, K | 1 |
| Blumenkrantz, MJ | 1 |
| Jones, MR | 1 |
| Tallos, J | 1 |
| Roberts, C | 1 |
| Card, B | 1 |
| Saltzman, R | 1 |
| Swendseid, ME | 2 |
| Ono, K | 1 |
| Ono, T | 1 |
| Matsumata, T | 1 |
| Eickholt, JT | 1 |
| Bergstralh, EJ | 1 |
| Wilson, DM | 1 |
| Smith, LH | 1 |
| Chimata, M | 1 |
| Masaoka, H | 1 |
| Fujimaki, M | 1 |
| Hamada, N | 1 |
| Oda, K | 1 |
| Sudo, M | 1 |
| Nagase, M | 1 |
| Mydlik, M | 5 |
| Derzsiová, K | 5 |
| Siskind, MS | 1 |
| Thienemann, D | 1 |
| Kirlin, L | 1 |
| Cheung, WC | 1 |
| Lo, CY | 1 |
| Ip, M | 1 |
| Cheng, IK | 1 |
| Mousson, C | 1 |
| Justrabo, E | 1 |
| Rifle, G | 1 |
| Sgro, C | 1 |
| Chalopin, JM | 1 |
| Gérard, C | 1 |
| Chauveau, P | 1 |
| Chadefaux, B | 1 |
| Coudé, M | 1 |
| Aupetit, J | 1 |
| Kamoun, P | 1 |
| Jungers, P | 2 |
| Asagi, K | 1 |
| Nakayama, M | 1 |
| Kobayashi, M | 1 |
| Awata, S | 1 |
| Nakayama, K | 1 |
| Kodama, H | 1 |
| Gupta, A | 2 |
| Dennis, V | 1 |
| Arheart, K | 2 |
| Chaudhary, D | 1 |
| Green, R | 1 |
| Vigo, P | 1 |
| Mayer, EL | 1 |
| Selhub, J | 3 |
| Kutner, M | 1 |
| Jacobsen, DW | 2 |
| Dennis, VW | 2 |
| Oner, A | 1 |
| Demircin, G | 1 |
| Ipekçioğlu, H | 1 |
| Bülbül, M | 1 |
| Ecin, N | 1 |
| Zemberová, E | 3 |
| Bostom, AG | 2 |
| Gohh, RY | 1 |
| Tsai, MY | 1 |
| Hopkins-Garcia, BJ | 1 |
| Nadeau, MR | 2 |
| Bianchi, LA | 1 |
| Jacques, PF | 2 |
| Rosenberg, IH | 2 |
| Shemin, D | 1 |
| Verhoef, P | 1 |
| Dworkin, L | 1 |
| Tamura, T | 1 |
| Bergman, SM | 1 |
| Morgan, SL | 1 |
| Hong, SY | 1 |
| Yang, DH | 1 |
| Chang, SK | 1 |
| Svác, J | 1 |
| Dlhopolcek, P | 1 |
| Rajnic, A | 1 |
| Marangella, M | 3 |
| Moustapha, A | 1 |
| Schreiber, MJ | 1 |
| Hörl, WH | 1 |
| Zingraff, J | 1 |
| Chadefaux-Vekemans, B | 1 |
| Massy, ZA | 1 |
| Lambert, J | 1 |
| Donker, AJ | 1 |
| Okada, H | 1 |
| Moriwaki, K | 1 |
| Kanno, Y | 1 |
| Sugahara, S | 1 |
| Nakamoto, H | 1 |
| Yoshizawa, M | 1 |
| Suzuki, H | 1 |
| Henning, BF | 2 |
| Tepel, M | 2 |
| Graefe, U | 2 |
| Zidek, W | 2 |
| Sunder-Plassmann, G | 1 |
| Winkelmayer, WC | 1 |
| Födinger, M | 1 |
| Naruszewicz, M | 1 |
| Klinke, M | 1 |
| Dziewanowski, K | 1 |
| Staniewicz, A | 1 |
| Bukowska, H | 1 |
| Weissgarten, J | 1 |
| Modai, D | 1 |
| Oz, D | 1 |
| Chen Levy, Z | 1 |
| Cohn, M | 1 |
| Marcus, O | 1 |
| Dishi, V | 1 |
| Galperin, E | 1 |
| Averbukh, Z | 1 |
| Dierkes, J | 1 |
| Domröse, U | 1 |
| Bosselmann, KP | 1 |
| Neumann, KH | 1 |
| Luley, C | 1 |
| McGregor, DO | 2 |
| Dellow, WJ | 2 |
| Lever, M | 2 |
| George, PM | 2 |
| Robson, RA | 2 |
| Chambers, ST | 2 |
| Riezler, R | 1 |
| Wrone, EM | 1 |
| Zehnder, JL | 1 |
| Hornberger, JM | 1 |
| McCann, LM | 1 |
| Coplon, NS | 1 |
| Sjögren, U | 1 |
| Thysell, H | 1 |
| Lindholm, T | 1 |
| Gäng, V | 2 |
| Schulz, RJ | 1 |
| Kult, J | 2 |
| Heidland, A | 1 |
| Vitale, C | 2 |
| Petrarulo, M | 2 |
| Cosseddu, D | 1 |
| Gallo, L | 1 |
| Linari, F | 2 |
| Allman, MA | 2 |
| Pang, E | 1 |
| Yau, DF | 2 |
| Stewart, PM | 2 |
| Tiller, DJ | 2 |
| Truswell, AS | 2 |
| Costello, JF | 1 |
| Sadovnic, MC | 1 |
| Smith, M | 1 |
| Stolarski, C | 1 |
| Guman, M | 1 |
| Hrehorovský, M | 1 |
| Gentile, MG | 2 |
| Porrini, M | 2 |
| Manna, GM | 1 |
| Ciceri, R | 1 |
| Cofano, F | 1 |
| Simonetti, P | 2 |
| D'Amico, G | 2 |
| Shah, GM | 2 |
| Ross, EA | 2 |
| Sabo, A | 2 |
| Pichon, M | 2 |
| Reynolds, RD | 2 |
| Bhagavan, H | 2 |
| Bianco, O | 1 |
| Finocchiaro, P | 1 |
| Latta, K | 1 |
| Brodehl, J | 1 |
| Watts, RW | 3 |
| Blumberg, EA | 1 |
| Gil, RA | 1 |
| Laso Guzmán, FJ | 1 |
| González-Buitrago, JM | 1 |
| Vela, R | 1 |
| Cava, F | 1 |
| de Castro, S | 1 |
| Tomson, CR | 1 |
| Channon, SM | 1 |
| Parkinson, IS | 1 |
| Sheldon, WS | 1 |
| Ward, MK | 1 |
| Laker, MK | 1 |
| Ciappellano, S | 1 |
| Testolin, G | 1 |
| Manna, G | 1 |
| Fellin, G | 1 |
| Horvath, JS | 1 |
| Duggin, GG | 1 |
| Barbari, A | 1 |
| Vaziri, ND | 1 |
| Benavides, I | 1 |
| Chen, YT | 1 |
| Said, H | 1 |
| Pahl, MV | 1 |
| Morgan, SH | 2 |
| Maher, ER | 1 |
| Purkiss, P | 2 |
| Curtis, JR | 1 |
| Mansell, MA | 1 |
| Baker, LR | 1 |
| Brown, CB | 1 |
| Ramirez, G | 2 |
| Chen, M | 2 |
| Boyce, HW | 2 |
| Fuller, SM | 2 |
| Ganguly, R | 1 |
| Brueggemeyer, CD | 2 |
| Butcher, DE | 2 |
| Newton, JL | 1 |
| Stein, G | 1 |
| Sperschneider, H | 1 |
| Koppe, S | 1 |
| McVicar, M | 1 |
| Gauthier, B | 1 |
| Goodman, CT | 1 |
| Solomons, CC | 1 |
| Goodman, SI | 1 |
| Riley, CM | 1 |
| Broyer, M | 1 |
| Berger, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis.[NCT03422159] | Phase 2 | 140 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease[NCT00384618] | Phase 4 | 100 participants | Interventional | 2001-05-31 | Terminated | ||
| CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)[NCT00032435] | Phase 3 | 2,003 participants (Anticipated) | Interventional | 2001-05-31 | Completed | ||
| Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria[NCT00280215] | Phase 3 | 0 participants (Actual) | Interventional | 2007-12-31 | Withdrawn (stopped due to Inadequate number of patients, lack of funding) | ||
| 5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients[NCT00626223] | 341 participants (Actual) | Interventional | 1998-01-31 | Completed | |||
| Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria[NCT00283387] | Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the day 4 post-randomization SOFA score minus the initial SOFA score. The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction). (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 2.9 |
| Placebo Arm | 1.93 |
Time from admitting to discharge of hospital stay. (NCT03422159)
Timeframe: From admission to the hospital until final discharge, up to 28 days.
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 11.5 |
| Placebo Arm | 11 |
In-hospital mortality rate. (NCT03422159)
Timeframe: Survival until hospital discharge, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 11 |
| Placebo Arm | 13 |
Time from admitting to ICU to discharge. (NCT03422159)
Timeframe: From admission to the ICU until final discharge from the ICU, up to an average of 7 days.
| Intervention | days (Mean) |
|---|---|
| Treatment Arm | 4.76 |
| Placebo Arm | 4.66 |
ICU mortality rate (NCT03422159)
Timeframe: From admission to hospital until final discharge from the ICU, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 6 |
| Placebo Arm | 10 |
PCT at 96 hours minus initial PCT, divided by the initial PCT multiplied by 100. (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | Percent (Mean) |
|---|---|
| Treatment Arm | 63 |
| Placebo Arm | 58 |
Defined as the time from starting the active treatment/placebo to discontinuation of all pressors. (NCT03422159)
Timeframe: From start of vasopressor medication to final discontinuation of vasopressor medication, up to 7 days.
| Intervention | hours (Mean) |
|---|---|
| HAT Treatment | 27 |
| Comparator | 53 |
Number of days alive and off of the ventilator at day 28. (NCT03422159)
Timeframe: 28 Days post-randomization
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 22 |
| Placebo Arm | 22.4 |
"The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.~Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period." (NCT00283387)
Timeframe: baseline, 2 months, 6 months
| Intervention | umol/mg (Mean) |
|---|---|
| Betaine | 1.43 |
| Placebo | 1.04 |
11 reviews available for pyridoxine and Chronic Kidney Failure
| Article | Year |
|---|---|
Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria.
Topics: Adult; Amino Acid Substitution; Arginine; Circadian Rhythm; Combined Modality Therapy; DNA Mutationa | 2013 |
The primary hyperoxalurias.
Topics: Alcohol Oxidoreductases; Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic; Kidney Transplanta | 2009 |
Oxalosis in infancy.
Topics: Consanguinity; Diagnosis, Differential; Female; Humans; Infant; Infant, Newborn; Kidney Failure, Chr | 1984 |
Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature.
Topics: Aged; Aged, 80 and over; Female; Humans; Isoniazid; Kidney Failure, Chronic; Male; Middle Aged; Nerv | 1993 |
Homocysteinemia and vascular disease in end-stage renal disease.
Topics: Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Kidney; Kidney Failure, Chronic; Kidney | 1996 |
Hyperhomocysteinemia as a cause of vascular occlusion in end-stage-renal disease.
Topics: Cardiovascular Diseases; Dietary Supplements; Folic Acid; Folic Acid Deficiency; Hematinics; Homocys | 1998 |
Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness.
Topics: Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic; Kidney Transplantation; Pyridoxine | 1999 |
Is there a role for adjuvant therapy in patients being treated with epoetin?
Topics: Androgens; Anemia; Angiotensin-Converting Enzyme Inhibitors; Ascorbic Acid; Carnitine; Cytokines; Er | 1999 |
Homocysteine and renal disease.
Topics: Adult; Arteriosclerosis; Cardiovascular Diseases; Case-Control Studies; Child; Endothelium, Vascular | 2000 |
Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Folic Acid; Homocysteine; Humans; Hyperh | 2000 |
Primary hyperoxaluria type I.
Topics: Age Factors; Alanine Transaminase; Child; Combined Modality Therapy; Female; Genes, Recessive; Human | 1990 |
15 trials available for pyridoxine and Chronic Kidney Failure
| Article | Year |
|---|---|
Effects of pyridoxine-HCl therapy on serum aminotransferase levels in haemodialysis patients.
Topics: Adult; Aspartate Aminotransferases; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pyri | 2006 |
Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxid
Topics: Administration, Oral; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Endoth | 2007 |
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Topics: Aged; Cause of Death; Double-Blind Method; Female; Folic Acid; Homocysteine; Humans; Kaplan-Meier Es | 2007 |
Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Creatinine; Female; Folic Acid; Homocysteine; Huma | 1996 |
Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 during continuous ambulatory peritoneal dialysis.
Topics: Adult; Ascorbic Acid; Dietary Proteins; Diuretics; Female; Furosemide; Humans; Kidney Failure, Chron | 1998 |
Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy.
Topics: Adult; Aged; Erythrocytes; Female; Humans; Hyperhomocysteinemia; Injections, Intravenous; Kidney Fai | 1999 |
Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy.
Topics: Age Factors; Analysis of Variance; Biomarkers; Blood Pressure; Brachial Artery; Carotid Artery, Comm | 2000 |
Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high-flux haemodialysis and human recombinant erythropoietin.
Topics: Chronic Disease; Diabetic Neuropathies; Erythropoietin; Female; Glomerulonephritis; Humans; Kidney F | 2000 |
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
Topics: Adult; Arteriosclerosis; Cholesterol; Creatinine; Drug Therapy, Combination; Female; Fibrinogen; Fol | 2001 |
Vitamin B(6) therapy does not improve hematocrit in hemodialysis patients supplemented with iron and erythropoietin.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspartate Aminotransferases; Dietary Supplemen | 2001 |
Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease.
Topics: Dietary Supplements; Dose-Response Relationship, Drug; Female; Folic Acid; Homocysteine; Humans; Hyp | 2001 |
Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.
Topics: Female; Folic Acid; Hematinics; Homocysteine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Py | 2001 |
An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
Topics: Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Ethnicity; Female; Folic Acid; Ge | 2001 |
Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure.
Topics: Aged; Betaine; Cross-Over Studies; Drug Therapy, Combination; Fasting; Female; Folic Acid; Hematinic | 2002 |
The influence of vitamin B6 supplementation on the bone marrow morphology in patients on regular haemodialysis treatment. A double-blind study.
Topics: Adult; Aged; Anemia; Bone Marrow; Bone Marrow Examination; Clinical Trials as Topic; Double-Blind Me | 1979 |
66 other studies available for pyridoxine and Chronic Kidney Failure
| Article | Year |
|---|---|
Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
Topics: Adult; Female; Homozygote; Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic; Middle Aged; Oxa | 2021 |
Type 1 primary hyperoxaluria: A case report and focus on bone impairment of systemic oxalosis.
Topics: Adult; Biopsy; Bone Density; Calcium Oxalate; Humans; Hyperoxaluria, Primary; Ilium; Kidney Failure, | 2018 |
Isoniazid cerebellitis in a peritoneal dialysis patient.
Topics: Antitubercular Agents; Cerebellar Diseases; Cerebellar Nuclei; Humans; Isoniazid; Kidney Failure, Ch | 2016 |
Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Consanguinity; Egypt; Female; Humans; Hyperoxaluria, | 2017 |
Quiz page October 2010: Anemia in a patient newly transferred from peritoneal dialysis to hemodialysis.
Topics: Anemia, Sideroblastic; Bone Marrow; Erythropoietin; Follow-Up Studies; Humans; Kidney Failure, Chron | 2010 |
Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study.
Topics: Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2004 |
Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study.
Topics: Adult; Cause of Death; Double-Blind Method; Folic Acid; Homocysteine; Hospitals, Veterans; Humans; H | 2004 |
Pyridoxal 5'-phosphate deficiency in uremic undialyzed, hemodialyzed, and non-uremic kidney transplant patients.
Topics: Adult; Apoenzymes; Female; Hot Temperature; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 1983 |
Successful renal transplantation in hyperoxaluria. A report of two cases.
Topics: Adult; Biopsy; Female; Follow-Up Studies; Graft Survival; Humans; Kidney; Kidney Calculi; Kidney Fai | 1983 |
Cadaveric renal transplantation in a patient with primary hyperoxaluria. A case report.
Topics: Adult; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Oxalates; Prognosis; Pyridoxin | 1983 |
Successful strategies for renal transplantation in primary oxalosis.
Topics: Adult; Biopsy; Calcium Oxalate; Child; Child, Preschool; Diuretics; Female; Humans; Infant; Kidney; | 1984 |
Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy.
Topics: Adult; Humans; Immunoglobulin G; Kidney Failure, Chronic; Lymphocytes; Male; Middle Aged; Neutrophil | 1984 |
Fluorometric study of serum in patients with chronic renal failure.
Topics: Adult; Creatinine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pyridoxine; Renal Dia | 1984 |
[Intra-erythrocytic GOT activity in uremia and its behavior following pyridoxine administration].
Topics: Aspartate Aminotransferases; Combined Modality Therapy; Erythrocytes; Humans; Kidney Failure, Chroni | 1983 |
Reduction of elevated plasma oxalic acid by pyridoxine therapy in patients on RDT.
Topics: Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Oxalates; Oxalic Acid; Pyridoxine | 1983 |
Primary hyperoxaluria.
Topics: Humans; Kidney Failure, Chronic; Kidney Transplantation; Metabolism, Inborn Errors; Oxalates; Pyrido | 1980 |
Secondary hyperoxalemia in chronic renal failure.
Topics: Blood; Calcinosis; Calcium Oxalate; Creatinine; Humans; Kidney Failure, Chronic; Oxalates; Oxalic Ac | 1982 |
[Water soluble vitamins in patients with chronic renal failure and effect of B6 administration on immunological activity (author's transl)].
Topics: Adult; Aged; Female; Humans; Immunoglobulins; Kidney Failure, Chronic; Male; Middle Aged; Pyridoxine | 1981 |
Daily requirement for pyridoxine supplements in chronic renal failure.
Topics: Adult; Alanine Transaminase; Erythrocytes; Female; Humans; Kidney Failure, Chronic; Male; Middle Age | 1981 |
The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chronic Disease; Female; Humans; Kid | 1995 |
Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.
Topics: Actuarial Analysis; Adolescent; Adult; Calcium Oxalate; Child; Child, Preschool; Female; Follow-Up S | 1994 |
Low serum aminotransferase activity in patients undergoing regular hemodialysis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Humans; Kidney Failure, Chronic; Middle Ag | 1994 |
Erythrocyte vitamins B1, B2 and B6 and erythropoietin.
Topics: Anemia; Erythrocytes; Erythropoietin; Humans; Kidney Failure, Chronic; Pyridoxine; Recombinant Prote | 1993 |
Isoniazid induced encephalopathy in dialysis patients.
Topics: Adult; Confusion; Female; Humans; Isoniazid; Kidney Failure, Chronic; Middle Aged; Pyridoxine; Renal | 1993 |
Piridoxilate-induced oxalate nephropathy can lead to end-stage renal failure.
Topics: Aged; Angina Pectoris; Ascorbic Acid; Calcium Oxalate; Creatinine; Drug Interactions; Female; Humans | 1993 |
Content of sulfur amino acids and vitamin B6 and related enzyme activities in rats with chronic renal failure fed a high methionine diet.
Topics: Amino Acids, Sulfur; Animals; Blood Urea Nitrogen; Body Weight; Creatinine; Cystathionine; Cystathio | 1996 |
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.
Topics: Aged; Aging; Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Kidney Failure, Chronic; Ma | 1996 |
Etiological and clinical patterns of urolithiasis in Turkish children.
Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Bacteriuria; Benzothiadiazines; Child; Child, Presch | 1997 |
Metabolism of vitamin B6 and its requirement in chronic renal failure.
Topics: Adult; Diuretics; Erythropoietin; Furosemide; Humans; Immunity, Cellular; Injections, Intravenous; K | 1997 |
Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients.
Topics: Adult; Aged; Arteriosclerosis; Fasting; Female; Folic Acid; Homocysteine; Humans; Kidney Failure, Ch | 1997 |
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cohort Stud | 1997 |
Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid.
Topics: Adult; Female; Folic Acid; Homocysteine; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle | 1998 |
[The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure].
Topics: Adult; Ascorbic Acid; Diuretics; Female; Furosemide; Humans; Kidney Failure, Chronic; Male; Middle A | 1998 |
Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.
Topics: Creatinine; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Kidney Failure, Chronic; Periton | 1999 |
[Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement].
Topics: Adult; Aged; Arteriosclerosis; Cysteine; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteine | 2000 |
Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Betaine; Betaine-Homocysteine S-Methyltransferase; | 2001 |
Water soluble vitamins in patients with chronic renal failure and effect of B6 administration of immunological activity.
Topics: Ascorbic Acid; Folic Acid; Humans; Kidney Failure, Chronic; Lymphocytes; Pyridoxine; Renal Dialysis; | 1979 |
Nutritional implications of renal disease. III. Nutritional needs of patients with renal disease.
Topics: Acute Kidney Injury; Amino Acids; Animals; Calcium; Humans; Kidney Diseases; Kidney Failure, Chronic | 1977 |
[Vitamin B6-deficiency and -substitution in chronic uremia (author's transl)].
Topics: Humans; Kidney Failure, Chronic; Pyridoxal Phosphate; Pyridoxine; Renal Dialysis; Vitamin B 6 Defici | 1975 |
Pathogenesis of severe hyperoxalaemia in Crohn's disease-related renal failure on maintenance haemodialysis: successful management with pyridoxine.
Topics: Adult; Crohn Disease; Humans; Kidney Failure, Chronic; Male; Oxalates; Pyridoxine; Renal Dialysis | 1992 |
Elevated plasma vitamers of vitamin B6 in patients with chronic renal failure on regular haemodialysis.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Kidney Failure, Chronic; Male; Mi | 1992 |
Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients.
Topics: Alanine Transaminase; Creatinine; Humans; Hyperoxaluria; Kidney Calculi; Kidney Failure, Chronic; Ox | 1992 |
Vitamin B6 requirements in chronic renal failure.
Topics: Adult; Follow-Up Studies; Humans; Kidney Failure, Chronic; Nutritional Requirements; Peritoneal Dial | 1992 |
Water- and fat-soluble vitamin status in chronic renal insufficiency patients.
Topics: Adult; Aged; Diet; Humans; Kidney Failure, Chronic; Middle Aged; Pyridoxine; Retinol-Binding Protein | 1992 |
Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.
Topics: Aged; Ascorbic Acid; Humans; Hyperoxaluria; Kidney Failure, Chronic; Male; Middle Aged; Oxalates; Pe | 1992 |
Primary hyperoxaluria: therapeutic strategies for the 90's.
Topics: Adult; Alanine Transaminase; Algorithms; Calcium Oxalate; Child; Combined Modality Therapy; Humans; | 1991 |
Glycolate determination detects type I primary hyperoxaluria in dialysis patients.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Glycolates; Humans; Hyperoxaluria, Primary; | 1991 |
Ascorbic acid supplements in patients receiving chronic peritoneal dialysis.
Topics: Aged; Ascorbic Acid; Diet; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Requireme | 1991 |
Treatment of renal failure in the primary hyperoxalurias.
Topics: Adult; Calcium Oxalate; Child; Combined Modality Therapy; Humans; Hyperoxaluria; Kidney Calculi; Kid | 1990 |
Cerebellar syndrome caused by isoniazid.
Topics: Aged; Cerebellar Diseases; Female; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Pyridox | 1990 |
Vitamin B6 status in uremia.
Topics: Adult; Aged; Aged, 80 and over; Aspartate Aminotransferases; Creatinine; Erythrocytes; Female; Human | 1990 |
Effect of pyridoxine supplementation on plasma oxalate concentrations in patients receiving dialysis.
Topics: Aspartate Aminotransferases; Erythrocytes; Humans; Kidney Failure, Chronic; Oxalates; Oxalic Acid; P | 1989 |
Thiamin, riboflavin and pyridoxine status in chronic renal insufficiency.
Topics: Dietary Proteins; Female; Food Analysis; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nutriti | 1989 |
Vitamin supplementation of patients receiving haemodialysis.
Topics: Ascorbic Acid; Female; Humans; Kidney Failure, Chronic; Male; Pyridoxine; Renal Dialysis; Riboflavin | 1989 |
Intestinal transport of pyridoxine in experimental renal failure.
Topics: Animals; Intestinal Absorption; Jejunum; Kidney Failure, Chronic; Male; Organ Culture Techniques; Pe | 1989 |
Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.
Topics: Adult; Aged; Ascorbic Acid; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxalates; Pe | 1988 |
Timing of renal transplantation in the management of pyridoxine-resistant type I primary hyperoxaluria.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Kidney Fa | 1988 |
Longitudinal follow-up of chronic hemodialysis patients without vitamin supplementation.
Topics: Adult; Aged; Ascorbic Acid; Female; Folic Acid; Follow-Up Studies; Humans; Kidney Failure, Chronic; | 1986 |
[Oxalic acid metabolism in chronic renal failure].
Topics: Ascorbic Acid; Aspartate Aminotransferases; Combined Modality Therapy; Erythrocytes; Glycolates; Hum | 1985 |
The plasma and red cell vitamin B levels of chronic hemodialysis patients: a longitudinal study.
Topics: Adult; Aged; Erythrocytes; Female; Folic Acid; Humans; Kidney Failure, Chronic; Longitudinal Studies | 1986 |
Deranged concentrations of water-soluble vitamins in the blood of undialyzed and dialyzed patients with chronic renal failure.
Topics: Adult; Aged; Ascorbic Acid; Female; Folic Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1986 |
Vitamin levels in chronic renal failure and need for supplementation.
Topics: Ascorbic Acid; Avitaminosis; Biotin; Folic Acid; Humans; Kidney Failure, Chronic; Niacin; Pantotheni | 1985 |
Uremic neuropathy. Monitoring of transketolase activity inhibition in a child.
Topics: Brain; Child; Electromyography; Female; Humans; Kidney Failure, Chronic; Leg; Nervous System Disease | 1973 |
[Vitamin B 6 in the serum during hemodialysis and chronic uremia].
Topics: Chronic Disease; Humans; Kidney Failure, Chronic; Pyridoxine; Renal Dialysis; Uremia; Vitamin B Defi | 1974 |
Calcium carbimide in the treatment of primary hyperoxaluria.
Topics: Child; Cyanates; Diet Therapy; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Metabo | 1967 |
[Oxalosis].
Topics: Acidosis, Renal Tubular; Alcohol Oxidoreductases; Allopurinol; Biopsy; Blood Urea Nitrogen; Calcium | 1968 |